{"id":"NCT01204398","sponsor":"Boehringer Ingelheim","briefTitle":"Telmisartan+Amlodipine Fixed Dose Combination in Hypertension","officialTitle":"An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2011-07","completion":null,"firstPosted":"2010-09-17","resultsPosted":"2012-08-24","lastUpdate":"2014-06-27"},"enrollment":27,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"telmisartan+amlodipine fixed dose combination","otherNames":[]}],"arms":[{"label":"eligible hypertension patient","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this trial is to evaluate the changes from baseline (Visit 2) in the 24-hour Ambulatory Blood Pressure Monitoring mean (relative to dose time) for diastolic blood pressure and systolic blood pressure after 8 weeks of treatment with Telmisartan 80mg/Amlodipine 5mg in patients with moderate to severe hypertension","primaryOutcome":{"measure":"DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean","timeFrame":"8 weeks","effectByArm":[{"arm":"T80/A5","deltaMin":-12.76,"sd":7.42}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":[]}}